Evidence map›Paper›PMID 36521546›Full record

ArticleLife sciences2023

Deleterious effects of cardiomyocyte-specific prostaglandin E2 EP3 receptor overexpression on cardiac function after myocardial infarction.

DruAnne L Maxwell, Timothy D Bryson, David Taube, Jiang Xu, Edward Peterson, Pamela Harding

Open access · hybridAbstract read
In one paragraph

Article in Life sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Prostanoids in Cardiac and Vascular Remodeling.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Review
  8. Prostaglandin E2 affects mitochondrial function in adult mouse cardiomyocytes and hearts.Prostaglandins, leukotrienes, and essential fatty acids · 2024
    Article
  9. The Link between Prostanoids and Cardiovascular Diseases.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

DruAnne L MaxwellDepartment of Physiology, Wayne State University School of Medicine, USA; Hypertension and Vascular Research Division, Department of Internal Medicine, Henry Ford Health, Detroit, MI, USA.
Timothy D BrysonHypertension and Vascular Research Division, Department of Internal Medicine, Henry Ford Health, Detroit, MI, USA.
David TaubeHypertension and Vascular Research Division, Department of Internal Medicine, Henry Ford Health, Detroit, MI, USA.
Jiang XuHypertension and Vascular Research Division, Department of Internal Medicine, Henry Ford Health, Detroit, MI, USA.
Edward PetersonDepartment of Public Health Sciences, Henry Ford Health, Detroit, MI, USA.
Pamela HardingDepartment of Physiology, Wayne State University School of Medicine, USA; Hypertension and Vascular Research Division, Department of Internal Medicine, Henry Ford Health, Detroit, MI, USA. Electronic address: phardin1@hfhs.org.
Wayne State University · USHenry Ford Health System · US

Funding

Opposing Effects of Prostaglandin E2 EP3 and EP4 Receptors on Mitochondrial Function in the Failing HeartR01HL148060 · NHLBI · WAYNE STATE UNIVERSITY · PI HARDING, PAMELA · 2020 to 2023
$2.2M
NHLBI NIH HHS R01 HL148060
6 · The paper itself

Abstract

aimsProstaglandin E2 (PGE2) is a lipid hormone that signals through 4 different G-protein coupled receptor subtypes which act to regulate key physiological processes. Our laboratory has previously reported that PGE2 through its EP3 receptor reduces cardiac contractility at the level of isolated cardiomyocytes and in the isolated working heart preparation. We therefore hypothesized that cardiomyocyte specific overexpression of the PGE2 EP3 receptor further decreases cardiac function in a mouse model of heart failure produced by myocardial infarction. MAIN

methodsOur study tested this hypothesis using EP3 transgenic mice (EP3 TG), which overexpress the porcine analogue of human EP3 in the cardiomyocytes, and their wildtype (WT) littermates. Mice were analyzed 2 wks after myocardial infarction (MI) or sham operation by echocardiography, RT-PCR, immunohistochemistry, and histology. KEY

findingsWe found that the EP3 TG sham controls had a reduced ejection fraction, reduced fractional shortening, and an increased left ventricular dimension at systole and diastole compared to the WT sham controls. Moreover, there was a further reduction in the EP3 TG mice after myocardial infarction. Additionally, single-cell analysis of cardiomyocytes isolated from EP3 TG mice showed reduced contractility under basal conditions. Overexpression of EP3 significantly increased cardiac hypertrophy, interstitial collagen fraction, macrophage, and T-cell infiltration in the sham operated group. Interestingly, after MI, there were no changes in hypertrophy but there were changes in collagen fraction, and inflammatory cell infiltration. SIGNIFICANCE: Overexpression of EP3 reduces cardiac function under basal conditions and this is exacerbated after myocardial infarction.

Indexed as

Myocardial InfarctionMyocytes, CardiacReceptors, Prostaglandin E, EP3 SubtypeAnimalsCardiomegalyCollagenDinoprostoneHumansMiceMice, TransgenicReceptors, ProstaglandinSwineCollagenDinoprostoneReceptors, ProstaglandinReceptors, Prostaglandin E, EP3 SubtypeEP3Myocardial infarctionProstaglandin E2

Identifiers

PMID36521546
PMCPMC9805516
OpenAlexW4313333887

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.